NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT04711135 2026-02-12NETTER-PAdvanced Accelerator ApplicationsPhase 2 Active not recruiting11 enrolled 14 charts 1 FDA